Surrozen Major Shareholder Boosts Stake with $881,573 Stock Purchase

Tcg Crossover Gp Ii, Llc increases ownership in the biotech company to 5.54%

Mar. 17, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Tcg Crossover Gp Ii, Llc, a major shareholder of Surrozen, Inc. (NASDAQ:SRZN), has purchased an additional 35,433 shares of the company's stock for a total of $881,573.04. This transaction increases Tcg Crossover Gp Ii, Llc's ownership stake in Surrozen to 675,018 shares, or 5.54% of the company.

Why it matters

Insider buying activity can be a signal of confidence in a company's future prospects. Tcg Crossover Gp Ii, Llc's increased stake in Surrozen suggests the major shareholder sees value in the biotech firm, which is developing novel therapeutic antibodies targeting the Wnt signaling pathway for tissue repair, regeneration, and oncology applications.

The details

Tcg Crossover Gp Ii, Llc acquired the 35,433 Surrozen shares at an average price of $24.88 per share on March 13, 2026. This transaction was disclosed in a filing with the Securities and Exchange Commission. The purchase increases Tcg Crossover Gp Ii, Llc's total ownership in Surrozen to 675,018 shares, valued at approximately $16.79 million.

  • On March 13, 2026, Tcg Crossover Gp Ii, Llc purchased 35,433 shares of Surrozen stock.
  • On March 16, 2026, Tcg Crossover Gp Ii, Llc acquired an additional 1,190 shares of Surrozen stock.
  • Between February 2-12, 2026, Tcg Crossover Gp Ii, Llc made several other purchases totaling 35,916 Surrozen shares.

The players

Tcg Crossover Gp Ii, Llc

A major shareholder of Surrozen, Inc. that has increased its ownership stake in the biotech company through multiple stock purchases.

Surrozen, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology.

Got photos? Submit your photos here. ›

What they’re saying

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

Tcg Crossover Gp Ii, Llc's increased investment in Surrozen suggests the major shareholder sees significant potential in the biotech company's pipeline of Wnt-targeting therapeutic antibodies. This insider buying activity could signal confidence in Surrozen's future growth prospects among key investors.